MAM
Mukesh Garg named managing director for Ramboll India
MUMBAI: Ramboll has announced the appointment of Mukesh Garg as its new managing director for India, effective 1 January 2025. A dynamic leader with 26 years of experience, Mukesh is set to bring his tech-savvy vision and transformational leadership skills to the forefront of Ramboll’s India operations. But wait, there’s more—he’s also juggling this role alongside his current position as senior director, head of technology operations in Ramboll Tech. Talk about multitasking!
Garg is no stranger to Ramboll. Joining the company in February 2020 as IT director, he quickly made his mark by leading the company’s Global IT transformation. By April 2024, he took on the mantle of senior director, technology operations, showcasing his flair for tech and leadership.
But Garg isn’t just a tech guru. With 18 years of senior global leadership experience across companies like Larsen & Toubro Infotech, AstraZeneca, and Flextronics Technologies, he’s an all-rounder. He’s built global capability centres (GCCs), simplified business processes, and run large-scale programs—all with a knack for fostering collaboration. Essentially, he’s the kind of person you’d want steering the ship when navigating the turbulent seas of today’s business world.
Ramboll group chief people officer Lone Tvis couldn’t be more thrilled about the appointment, “I’m delighted that Mukesh has agreed to take on the role as managing director for India in addition to his current role. With his leadership skills, strategic vision, and contributions towards building an organisation fit for the future, I know he is the right person for the job. I’m confident that with his strong international leadership background and diverse business experience, he will contribute to making Ramboll an attractive workplace, a collaborative business, and a true partner for sustainable change for our clients.”
That’s a glowing endorsement if there ever was one. But what does Garg have to say about this exciting new chapter? In his own words, he expressed pride in his journey at Ramboll and a deep commitment to fostering an inclusive, innovative environment, “It has been a pleasure working with great colleagues in Ramboll for the past five years. I’m proud to be working for a foundation-owned, globally integrated company with strong values, and it will be my endeavour to create an enabling and engaging environment where our bright minds can thrive. I look forward to advancing the global vision of becoming an outstanding business and a talent powerhouse of global capabilities.”
Ambitious, isn’t he? But with Garg’s track record, we wouldn’t bet against him pulling it off.
In a world where innovation and sustainability are no longer optional, Garg’s leadership could be the game-changer Ramboll needs.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
